Published in Cancer Law Weekly, April 8th, 2006
In a notice posted March 7, 2006, to its official website, the United States Patent & Trademark Office (USPTO) indicated it has granted a patent on the PCA3 gene technology, which encompasses both therapeutic and diagnostic applications. The U.S. patent 7,008,765 "PCA3, PCA3 genes, and methods of use" is at the forefront of several families of patent applications covering PCA3, its structure, and its role in the diagnosis, prognosis, and therapeutics of prostate...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.